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Summary
Background: Although the demonstration of leptomeningeal
dissemination is the most important predictor of poor outcome
in children with medulloblastoma, there is lack of consensus
on the prognostic value of a positive cerebrospinal fluid (CSF)
cytology (i.e., stage Ml).
Patients and methods: Eighty-six pediatric medulloblasto-
ma patients treated in Switzerland between 1972-1991 were
retrospectively studied regarding the influence of M-stage on
prognosis. 39 were MO, 13 Ml, 15 Mx, 17 M2, and 2 M3.
Results: Five- and 10-year overall survival rates were 76%
and 54% for MO, 68% and 50% for Mx, 36% and 25% for Ml,
and 22% and 22% for M2-3 (P < 0.001), respectively. No
significant survival differences were observed between Ml and
M2-3 patients. Among 26 patients with only postoperative
CSF cytologies, seven were positive. Their outcome was similar
to that of six preoperatively staged Ml and significantly different
from that of M0 patients (P = 0.001). In 14 patients both pre-
and postoperative CSF cytology was performed. Total agree-
ment was observed between the pre- and postoperative results
(six positive and eight negative). Among the 19 M2-3 patients
CSF cytology was positive in eight, negative in five, and
unknown in six.
Conclusions: A positive CSF cytology either pre- or post-
operatively predicts for a poor outcome, similar to that observed
in stage M2-3 patients. A postoperative cytology is likely to be
concordant with cytologic results obtained preoperatively, and
seems to have the same prognostic significance. A negative
cytology, however, does not exclude a more advanced stage.
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Introduction Patients and methods
The presence of leptomeningeal involvement at the time
of diagnosis is the most powerful predictor of unfavor-
able outcome in children treated for medulloblastoma
[2-4]. However, although cerebrospinal fluid (CSF) cytol-
ogy is an important component of the most widely used
staging system, the prognostic value of a positive cytology
remains controversial. A 1995 report of results from a
trial of the International Society of Pediatric Oncology
[4] concluded that the presence of leptomeningeal metas-
tases was the only factor related to poor survival, despite
the fact that CSF cytology was not taken into account,
nor was spinal imaging mandatory to rule out sub-
arachnoidal spread. Moreover, it has been suggested [2,
5] that a positive postoperative CSF cytology may be the
result of surgical shedding and is therefore of doubtful
prognostic value. The purpose of the present study was
to retrospectively assess the prognostic value of CSF
cytology at diagnosis in a consecutive series of pediatric
medulloblastoma patients treated in Switzerland over a
20-year period.
Eighty-six children and adolescents with a diagnosis of medulloblasto-
ma were treated at the Swiss University and Cantonal Hospitals during
the period 1972 to 1991. All clinical and treatment records were re-
viewed. Open surgery was carried out in all patients. Resection was
considered complete in 30 patients, subtotal in 42 patients, and in 14
cases only a biopsy or partial resection (minor debulking) was under-
taken.
Postoperative megavoltage radiotherapy (RT) was delivered to all
patients, in the form of craniospinal axis irradiation, followed by a boost
to the posterior fossa. The midplane dose prescribed to the whole brain
in the beam axis was < 30 Gy in 18 patients (no patient received < 23.4
Gy), 30-35 Gy in 21 patients, and > 35 Gy in 47 patients (no patient
received > 45 Gy). The spine was treated with a single posterior field or
a pair of two abutting posterior fields including the dural sac from C2-
C4 to S2 were used. The prescribed dose was < 30 Gy in 30 patients,
30-35 Gy in 24 patients, and > 35 Gy in 32 patients. The total dose
delivered to the posterior fossa at the reference point was < 54 Gy in
27 patients and > 54 Gy in 59 patients.
Adjuvant chemotherapy was given to 62 of the 86 children after
radiotherapy according to one of the following protocols: vincristine,
procarbazine and prednisone (1972-1981); nitrogen mustard, vincristine,
procarbazinc and prednisone (MOPP; 1982-1984); vincristine and
CCNU (1985-1986); cisplatin and etoposide followed by vincristine
and cyclophosphamide (1990-1991). Between 1987 and 1989 a two
month schedule of chemotherapy (vincristine, cisplatin, and cyclo-
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Table I. Clinical characteristics for 86 medulloblastoma patients
treated from 1972 to 1991.
Feature Number of patients (%)
Age (m years)
Median
Range
Sex
Male
Female
T-stage (Chang)
T2
T3
T4
Tx
CSF cytology
Positive
Negative
Unknown
M-stage (Chang)
MO
Ml
M2
M3
Mx
8.2
1.7-18
66(77)
20(23)
24(28)
46(53)
13(15)
3(3)
18(21)
47(55)
21 (24)
39(45)
13(15)
17(20)
2(2)
15(17)
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Figure 1. Overall survival curves (Kaplan-Meier) by M-stage at
diagnosis: MO vs. Ml vs. M2-3 vs. Mx.
phosphamide) was 'sandwiched' between surgical resection and the
start of RT. Inclusion of patients in adjuvant chemotherapy protocols
were unrelated to established clinical risk factors.
The patients' clinical characteristics are summarized in Table I.
Both T-stage and M-stage were assigned retrospectively according to
the guidelines of Chang et al. [6]. T-stage was determined by review of
operative reports. Disease spread had been investigated using standard
radiologic tools considered appropriate at the time of diagnosis (i.e.,
pneumoencephalogram, radioisotopic brain scan, computerized tomog-
raphy, magnetic resonance imaging). A systematic search for drop
metastases to the spinal theca was not done in all patients. Only 22
patients underwent either myelography and/or spinal MRI (2 of 53
before 1986, and 20 of 33 thereafter).
CSF cytologies were available in 65 patients (76%). Preoperative
CSF cytologies were done at the time of ventricular shunting, prior to
posterior fossa surgery. Postoperative CSF cytologies were obtained
from lumbar punctures performed during the first two weeks after
surgery. During the time of this study no general guidelines were in
force regarding cytological examination of CFS in pediatric brain
tumor patients. The techniques used were therefore those that had be
adopted by the institute of pathology in each participating institution.
A central pathology review for the purpose of this study was not
performed. Fifty-two children were staged exclusively on cytologic
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Figure 2. Overall survival curves (Kaplan-Meier) for Ml patients
staged either preoperatively or postoperatively.
grounds (MO if negative; MI if positive); 12 had only preoperative
cytologies, 26 only postoperative cytologies, and 14 both pre- and
postoperative cytologies. From 54 patients coded as 'non-melastatic'
(MO) in the Swiss pediatric tumor registry, documentation of negative
CSF cytology was found in only 39 at the time of review. In summary,
39 patients were MO (negative cytology); 13 Ml (positive cytology); 17
M2 (gross cerebral or cerebellar subarachnoidal invasion); 2 M3 (gross
subarachnoidal spinal seeding); and 15 Mx (cytology unknown).
Overall survival was calculated according to the Kaplan-Meier
method. The log-rank test was used to examine the correlation of
survival with M-stage (i.e., MO versus Mx versus Ml versus M2-3) as
well as with with pertinent subgroups (e.g., pre- versus postoperative
positive CSF cytology).
Results
Five- and 10-year overall survival rates were 76% and
54% for stage MO, 36% and 25% for stage Ml, 22% and
22% for stages M2-3, and 68% and 50% for stage Mx,
respectively (P < 0.001, Figure 1). Overall survival did
not differ significantly between stage MO and stage Mx
patients (P = 0.812), or between stage Ml and stage
M2-3 patients (P = 0.376). Among 26 children with
only postoperative CSF cytologic staging, a positive
cytology was observed in seven cases. Their survival
was significantly worse than that of MO patients (P =
0.001) and similar to that of six Ml patients whose stage
was determined exclusively by preoperative cytology
(P = 0.168, Figure 2). In 14 patients both pre- and post-
operative CSF cytology was performed. Total agreement
was observed between the pre- and postoperative results
(six positive, eight negative). However, among the 17 M2
patients (gross cerebral or cerebellar subarachnoidal
invasion) CSF cytology was positive in only three cases,
was negative in eight, and was unknown in six. CSF
cytology was positive in both M3 patients.
Discussion
In the present study a positive CSF cytology was in itself
strongly predictive of an unfavorable outcome after
treatment of pediatric medulloblastoma. The overall
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survival of Ml and M2-3 patients was similar, and in
both cases significantly different from that of MO pa-
tients. Deutsch [7] reported comparable results in 52
medulloblastoma patients, all of whom had undergone
myelography and all but two cytologic analysis of at
least one CSF sample taken from a shunt or a spinal
puncture site. Failure rates for MO, Ml, and M2-3
patients were 25%, 50%, and 60%, respectively. Further-
more, Evans et al. [2] reported on 233 medulloblastoma
patients included in a randomized trial of the Childrens
Cancer Study Group. In patients staged as MO, CSF
cytology or myelography were performed in only 56%
and 11%, respectively. Nevertheless, the five-year event-
free survival rate in this group of inadequately staged
MO patients was 59%, significantly higher than the 40%
rate observed in Ml patients. There were no significant
differences in survival rates between Ml, M2, and M3
patients. Finally, Merchant et al. [3], reported on 100
medulloblastoma patients who underwent rigorous stag-
ing procedures: CSF cytology in 95%, and myelogram
or MRI in 94%. Again, CSF cytology was highly pre-
dictive of overall and disease-free survival in uni- and
multivariate analysis. These results are consistent with
the notion that a positive cytology is a powerful prog-
nostic indicator, associated with an outcome similar to
that of patients staged as M2 or M3.
The small proportion of M3 patients observed in the
present study most likely reflects the infrequent use of
spinal imaging prior to 1986. This is in contrast with a
much higher availability of CSF cytologic information
at diagnosis (76% of children). In Deutsch's report [7]
among 18 patients with positive cytologies at diagnosis,
11 had positive myelograms. Thus, one might speculate
that a similar proportion of our Ml patients might have
been understaged. Although understaging might diminish
the prognostic value of an isolated positive CSF cytology,
this did not seem to be the case in Deutsch's [7] and
Merchant's et al. [3} reports, in which similar low survival
rates were observed for Ml vs. M2-3 stages, even when
adequate staging procedures were used.
The importance of the timing of the cytologic exami-
nation is controversial. Unlike Balhuizen et al. [5], who
observed a higher incidence of positive CSF cytologies
at postoperative than at preoperative evaluation, in both
our study and that of Deutsch [7], a similar proportion
of positive pre- and post-operative cytologies was found.
Furthermore, among 14 patients in our study in whom
pre- and postoperative CSF cytologies were performed,
complete agreement was observed between both results.
This high level of concordance was not found by Deutsch
and Reigel [8], who observed among patients with both
pre- and postoperative CSF cytologies that in four pa-
tients with positive postoperative cytologies only one was
positive, but three negative before surgery. No informa-
tion was provided, however, regarding the clinical course
of the three patients with 'false' positive postoperative
cytologies. In the present study survival of Ml patients
staged by lumbar puncture after surgery was not differ-
ent from that of Ml patients assessed preoperatively
(Figure 3), suggesting that a positive CSF cytology
correlates with a poor outcome, regardless of the time
of assessment. To our knowledge there are no other data
in the literature addressing this particular point.
In summary, between 20%-30% of pediatric medullo-
blastoma patients have a positive CSF cytology. The rate
of positivity appears similar whether determined either
pre- and postoperatively, and the results are generally
(but not always) concordant. Pre- and postoperative
positive cytologies both appear to predict for a poor
outcome, similar to that associated with stages M2 and
M3. However, a negative cytology does not always
exclude a more advanced stage, in that cytology was
negative in 8 out of 11 evaluable M2 patients in the
present study. These data underscore the usefulness of
CSF cytology in medulloblastoma staging, but support
the continued use of other staging procedures, including
spinal imaging.
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